Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 19/20 | 0.66 |
| ▸ | PSMB5 | P28074 | 17/20 | 0.66 |
| ▸ | PSMB9 | P28065 | 5/20 | 0.66 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.66 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.62 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21983221 | 1.00 | PSMB8 (0.66) | PSMB8PSMB5PSMB9PSMB1PSMB2 | |
| SCHEMBL20821038 | 0.95 | PSMB8 (0.70) | PSMB8PSMB5PSMB9PSMB1PSMB2 | |
| SCHEMBL8100922 | 0.95 | PSMB8 (0.70) | PSMB8PSMB5PSMB9PSMB1PSMB2 | |
| SCHEMBL20821188 | 0.93 | PSMB8 (0.59) | PSMB8PSMB5PSMB9PSMB1PSMB2 | |
| SCHEMBL19316011 | 0.93 | PSMB8 (0.59) | PSMB8PSMB5PSMB9PSMB1PSMB2 | |
| SCHEMBL16119374 | 0.92 | PSMB8 (0.60) | PSMB8PSMB5PSMB9PSMB1PSMB2 | |
| SCHEMBL20821200 | 0.92 | PSMB8 (0.60) | PSMB8PSMB5PSMB9PSMB1PSMB2 | |
| SCHEMBL16118890 | 0.91 | PSMB8 (0.57) | PSMB8PSMB5PSMB9PSMB1PSMB2 | |
| SCHEMBL15568779 | 0.89 | CTSS (0.58) | PSMB8PSMB5PSMB9PSMB1PSMB2 | |
| SCHEMBL15594256 | 0.89 | CTSS (0.58) | PSMB8PSMB5PSMB9PSMB1PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-RE47302-E1 | Peptide epoxyketone immunoproteasome inhibitors | ONYX THERAPEUTICS INC. (US) | 2019-03-19 | — | — | US | disclosed |
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2014152134-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | PSMB8 489/4885PSMB5 511/4885PSMB9 348/4885 |
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | PSMB8 489/4885PSMB5 511/4885PSMB9 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.